Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9207MR)

This product GTTS-WQ9207MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9207MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10564MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ11829MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-4280
GTTS-WQ14995MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ5653MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ6666MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ15692MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ5230MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ8398MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HS006
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW